Share on StockTwits

WuXi PharmaTech (NYSE:WX) was the target of a large decline in short interest during the month of May. As of May 15th, there was short interest totalling 312,742 shares, a decline of 40.1% from the April 30th total of 522,360 shares, reports. Approximately 0.4% of the shares of the company are short sold. Based on an average trading volume of 603,520 shares, the days-to-cover ratio is presently 0.5 days.

Several analysts have recently commented on the stock. Analysts at Morgan Stanley reiterated an “overweight” rating on shares of WuXi PharmaTech in a research note on Thursday, May 15th. They now have a $45.00 price target on the stock. Analysts at Zacks downgraded shares of WuXi PharmaTech from an “outperform” rating to a “neutral” rating in a research note on Wednesday, May 7th. They now have a $43.40 price target on the stock. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $39.88.

Shares of WuXi PharmaTech (NYSE:WX) opened at 32.72 on Thursday. WuXi PharmaTech has a 52-week low of $18.91 and a 52-week high of $40.72. The stock’s 50-day moving average is $34.28 and its 200-day moving average is $35.5. The company has a market cap of $2.337 billion and a P/E ratio of 21.51.

WuXi PharmaTech (NYSE:WX) last announced its earnings results on Wednesday, May 14th. The company reported $0.30 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.39 by $0.09. The company had revenue of $146.70 million for the quarter, compared to the consensus estimate of $145.00 million. During the same quarter in the previous year, the company posted $0.35 earnings per share. The company’s revenue for the quarter was up 11.2% on a year-over-year basis. On average, analysts predict that WuXi PharmaTech will post $1.84 earnings per share for the current fiscal year.

WuXi PharmaTech (NYSE:WX) Inc, (WuXi) is a pharmaceutical, biotechnology and medical device research and development (R&D) outsourcing company, with operations in People’s Republic of China and the United States.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.